SCHEMBL9909259

SCHEMBL9909259

COC(=O)c1cc(C)c2nccc(-c3ccc(OC)cc3Cl)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.38
DBF4 Q9UBU7 2/20 0.38
CCNT1 O60563 1/20 0.38
CSNK2A2 P19784 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CSNK1D P48730 1/20 0.38
CDK9 P50750 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
TYK2 P29597 2/20 0.37
JAK2 O60674 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909228 0.90 KDM5A (0.43) CDC7DBF4CCNT1CSNK2A2CCNE1
SCHEMBL9907493 0.89 CYP46A1 (0.39) CDC7DBF4CCNE1CDK2KDM4C
SCHEMBL9907455 0.89 ALPL (0.44) NPC1MAPTPOLB
SCHEMBL15500536 0.87 CDC7 (0.39) CDC7DBF4CCNT1CSNK2A2CCNE1
SCHEMBL9907419 0.87 MAPK14 (0.41) CDC7DBF4CYP1A2MAPTTP53
SCHEMBL9909233 0.84 CDC7 (0.39) CDC7DBF4CCNT1CSNK2A2CCNE1
SCHEMBL9907509 0.83 MRGPRX4 (0.40) KDM4CKDM5BKDM4ECYP1A2CYP2D6
SCHEMBL9909226 0.82 CCNT1 (0.44) CCNT1CDK9KMT2A
SCHEMBL9907445 0.81 NR1H2 (0.41) CCNT1CDK9KDM4ECYP1A2CYP2C19
SCHEMBL9907463 0.81 NR1H2 (0.44) KDM4CKDM4ECYP2C9CYP2C19PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E CDC7 4154/4885DBF4 3111/4885CCNT1 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.